11 September 2018 - The product's availability is expected in November 2018.

Merck Canada today announced the Health Canada approval of Stromectol (ivermectin), indicated for the treatment of intestinal strongyloidiasis and onchocerciasis, potentially devastating tropical parasitic infections.

The approval comes as global rates of migration and travel put growing numbers of Canadians at risk of parasitic infection.

Read Merck press release